Ocular Therapeutix begins phase 3 trial of sustained-release corticosteroid

A phase 3 clinical program will investigate the safety and efficacy of sustained-release dexamethasone, a corticosteroid to treat inflammation and pain after cataract surgery, according to a press release from Ocular Therapeutix. A one-time intracanalicular plug releases the steroid to the ocular surface for up to 30 days. Two prospective, multicenter, randomized, parallel-arm, doubled-masked, vehicle-controlled studies are planned.